Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).